iTeos Therapeutics
iTeos Therapeutics
ITOS
NASDAQ
7.52
USD
0.00%
About
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways.
Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment.
Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 289.4K |
| Three Month Average Volume | 6.9M |
| High Low | |
| Fifty-Two Week High | 18.75 USD |
| Fifty-Two Week Low | 8.2 USD |
| Fifty-Two Week High Date | 10 May 2024 |
| Fifty-Two Week Low Date | 12 Oct 2023 |
| Price and Volume | |
| Current Price | 16.85 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.74% |
| Thirteen Week Relative Price Change | -5.95% |
| Twenty-Six Week Relative Price Change | 35.98% |
| Fifty-Two Week Relative Price Change | 11.45% |
| Year-to-Date Relative Price Change | 29.95% |
| Price Change | |
| One Day Price Change | -0.06% |
| Thirteen Week Price Change | 0.66% |
| Twenty-Six Week Price Change | 49.51% |
| Five Day Price Change | -3.60% |
| Fifty-Two Week Price Change | 39.66% |
| Year-to-Date Price Change | 53.88% |
| Month-to-Date Price Change | -4.21% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 16.05075 USD |
| Book Value Per Share (Most Recent Quarter) | 18.17823 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 16.05075 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 18.17823 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.90887 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.35217 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.95167 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.14963 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.00049 USD |
| Normalized (Last Fiscal Year) | -3.14963 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.14963 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.00049 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.14963 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.00049 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 14.8422 USD |
| Cash Per Share (Most Recent Quarter) | 15.6423 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.12447 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.91131 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -3.198 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | 39 |
| Cash Flow Revenue (Trailing Twelve Months) | -336 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -292.80% |
| Pretax Margin (Last Fiscal Year) | -865.66% |
| Pretax Margin (5 Year) | 37.72% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,199.69% |
| Operating Margin (Trailing Twelve Months) | -413.78% |
| Operating Margin (5 Year) | 23.49% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -894.34% |
| Net Profit Margin (Trailing Twelve Months) | -308.96% |
| Net Profit Margin (5 Year) | 22.09% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 104.21% |
| Tangible Book Value (5 Year) | 107.23% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -59.30% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 68.45% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 81.28% |
| EPS Change (Trailing Twelve Months) | -264.69% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -571,256,000 |
| Net Debt (Last Fiscal Year) | -531,916,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 49 |
| Price to Sales (Trailing Twelve Months) | 18 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 14 |
| Current Ratio (Most Recent Quarter) | 18 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -106,821,000 |
| Free Cash Flow (Trailing Twelve Months) | -117,615,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -15.84% |
| Return on Assets (Trailing Twelve Months) | -14.86% |
| Return on Assets (5 Year) | 5.84% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -18.19% |
| Return on Equity (Trailing Twelve Months) | -16.80% |
| Return on Equity (5 Year) | 7.20% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -16.81% |
| Return on Investment (Trailing Twelve Months) | -15.55% |
| Return on Investment (5 Year) | 7.02% |